Aijing Shang

Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

Eric Van Cutsem, Walter L. Vervenne, Jaafar Bennouna et al. · Journal of Clinical Oncology · 2009 · 642 citations · Full text

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

Aimery de Gramont, Eric Van Cutsem, Hans‐Joachim Schmoll et al. · The Lancet Oncology · 2012 · 522 citations

Gastrointestinal Oncology, Medicine, Colorectal Cancer +7

AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer.

Armand de Gramont, Eric Van Cutsem, Josep Tabernero et al. · Journal of Clinical Oncology · 2011 · 81 citations

Surgical Oncology, Xelox Chemotherapy, Immunology +16

A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer

Walter L. Vervenne, Jaafar Bennouna, Yves Humblet et al. · Journal of Clinical Oncology · 2008 · 50 citations

Cancer Management, Prognosis, Median Overall Survival +19

Matched-pair study showed higher quality of placebo-controlled trials in Western phytotherapy than conventional medicine

Linda Nartey, Karin Huwiler-Müntener, Aijing Shang et al. · Journal of Clinical Epidemiology · 2007 · 26 citations

Non-pharmacological Intervention, Higher Quality, Medicine +11